Neuropace, Inc..
NPCE.US | Manufacture of medical and dental instruments and supplies
NeuroPace, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and marketing products for the treatment of neurological disorders. Its primary product is the RNS System, a closed-loop brain-computer interface that delivers personalized, responsive neurostimulation...Show More
Better Health for All
20
NeuroPace's core product, the RNS System, demonstrates significant positive health impacts for drug-resistant focal epilepsy. A 3-year post-approval study showed an 82% median reduction in seizures and 42% of patients achieved seizure freedom for 6+ months.
1
A 9-year study reported 35% of patients achieved at least 90% seizure frequency reduction and 28% had seizure-free periods, with lower SUDEP rates compared to refractory populations.
2
The company's R&D expense was $7.4 million in Q1 2025, representing 32.9% of its $22.5 million revenue for the quarter, indicating a strong investment in health innovation.
3
The company has received FDA approval for its RNS System.
4
The company's website includes safety information and advises consulting a doctor about risks and benefits.
5
However, specific adverse event rates from the 3-year post-approval study, for which safety and effectiveness data were submitted to the FDA in November 2024, are not provided.
6
A single adverse event report from 2017 detailed a lead fracture, though it resulted in no consequences or impact to the patient.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Neuropace, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Neuropace, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No quantitative evidence was found in the provided articles to assess Neuropace, Inc. against the Fair Trade & Ethical Sourcing value. outlines a Supplier Code of Conduct detailing expectations for ethical sourcing, labor practices, and environmental responsibility, including prohibitions against forced and child labor, and mandates for risk assessments and audits.
1
However, this document is a policy statement and does not provide specific data points on performance metrics such as the percentage of fair-trade certified spend, audit frequency, number of labor incidents, supply chain traceability, remediation speed, or the percentage of contracts with ethical clauses.
2
Articles and were inaccessible due to throttling.
3
Honest & Fair Business
0
No evidence available to assess Neuropace, Inc. on Honest & Fair Business.
Kind to Animals
-60
NeuroPace conducted animal studies, including lead implantation in sheep for 33 to 200 days, and biocompatibility testing in rabbits and guinea pigs.
1
These studies involved various device components and assessed neurotoxicity, local tissue responses, and systemic effects.
2
A separate study used eight male, castrated Suffolk sheep with survival periods of 6-9 months.
3
While the company performed in-vitro cytotoxicity testing, it also relied on extensive animal studies for safety assessments.
4
The company advocates for alternative testing methods like 'brains-on-chips' and 'human imaging techniques'.
5
There is no explicit company-wide animal testing policy stated in the provided articles.
6
The company does not mention participation in multi-stakeholder initiatives for animal-free R&D or active engagement in animal welfare policy improvement.
7
No War, No Weapons
0
No evidence available to assess Neuropace, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Neuropace, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, quantitative data points related to NeuroPace, Inc.'s respect for cultures and communities were found in the provided articles.
1
The available information explicitly states that sustainability data is unavailable and no quantitative data relevant to the requested metrics is presented.
2
Safe & Smart Tech
-10
NeuroPace encrypts data in transit and at rest for its nSight Platform and mentions data encryption as a general cybersecurity measure.
1
The company has no documented data breaches or incidents of unauthorized data use.
2
Users can request deletion of their data, subject to exceptions, and data portability is available, along with opt-out options for marketing materials.
3
Login credentials are required for access, and the company mentions user names, passwords, and access controls.
4
NeuroPace has a risk management process that includes vulnerability management and incident response, with reporting to the audit committee for certain incidents.
5
Security testing includes penetration testing, with third-party providers utilized.
6
The company states it collects only necessary data, but specific data minimization practices or retention schedules are not detailed.
7
NeuroPace mentions compliance with the HIPAA Security Rule and addresses CCPA for California residents, but explicitly states it does not claim GDPR compliance for personal data.
8
Zero Waste & Sustainable Products
0
No specific, quantifiable evidence was found in the provided articles to assess Neuropace, Inc. against any of the 'Zero Waste & Sustainable Products' KPIs. While one article mentioned 'recyclable device components' and 'eco-friendly manufacturing practices',
1
these statements lacked the specific percentages, numbers, or detailed outcomes required to score against the rubric's quantitative thresholds for product recyclability, waste diversion, or other related metrics.